I-Adiso Therapeutics, Inc. namuhla imemezele ukuthi isiqedile ukubhaliswa kweqembu layo lokuqala leziguli ocwaningweni lomtholampilo lweSigaba 1b oluhlola i-ADS051 (BT051), imodulator yomlomo, ekhawulelwe emathunjini, yokushushumbiswa kwe-neutrophil nokwenziwa kusebenze, njengendlela yokwelapha engaba khona. ezigulini ezine-ulcerative colitis emaphakathi-kuya-kanzima (UC). Idatha engaboni ibonise ukuthi ukudosa kuleli qoqo kwakuphephile futhi kubekezelelwe kahle, kusekela ukuqaliswa kokubhaliswa kweqoqo lesibili lomthamo ophezulu.
Lesi sigaba 1b siwucwaningo olungahleliwe, oluyimpumputhe oluphindwe kabili, olulawulwa yi-placebo, olukhuphuka kaningi ezigulini ezine-UC esebenzayo ngokumaphakathi kuya kokunzima (NCT05084261). Izinjongo eziyinhloko zalolu cwaningo ukuphepha nokubekezelelana okunenjongo yesibili ye-pharmacokinetics, kanye nezinjongo zokuhlola zokunciphisa ama-biomarker ahlobene ne-neutrophil. Lolu cwaningo lweSigaba 1b lulandela isifundo somthamo owodwa okhuphukayo weSigaba 1a kumavolontiya anempilo abonise ukuthi i-ADS051 ikhawulelwe amathumbu ngaphandle kobuthi obukhawulela umthamo noma izehlakalo ezimbi kakhulu.
“Ukukhomba ama-neutrophils kuyisu elisha lokwelapha i-pathophysiology eyisisekelo ye-ulcerative colitis. Lolu cwaningo lweSigaba 1b luyisinyathelo esilandelayo sokuhlola ukuthi i-ADS051 ingase ivimbe kanjani ngokuphephile nangempumelelo izindlela ezibalulekile ezaziwa ngokubangela ukufuduka nokusebenza kwama-neutrophils kukholoni lapho inqubo yokuvuvukala ebukhali ku-UC iqhubeka. Kulolu cwaningo sizobheka ama-biomarkers omsebenzi we-pharmacological kanye nezibonakaliso zokuqala zomsebenzi wezokwelapha ezingase zihumushe ekunciphiseni ukuvuvukala kwamakholoni futhi kukhuthaze ukuphulukiswa kwe-mucosal ezigulini ezine-UC ephakathi kuya kobunzima, "kusho uScott Megaffin, isikhulu esiphezulu, u-Adiso. "Ukuqhubeka nokuqhubekisela phambili ukuthuthukiswa komtholampilo kwe-ADS051 kubalulekile uma kubhekwa isidingo esikhulu esingafinyeleleki seziguli ezine-UC ezinemithi yokwelapha ekhawulelwe emathunjini embalwa eyingqayizivele yokushushumbiswa kwe-neutrophil."
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- today announced that it has completed enrollment of its first cohort of patients in a Phase 1b clinical study evaluating ADS051 (BT051), an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation, as a potential treatment for patients with moderately-to-severely active ulcerative colitis (UC).
- This Phase 1b study is the next step in exploring how ADS051 may safely and effectively inhibit key pathways known to cause the migration and activation of neutrophils in the colon where the acute inflammatory process in UC is ongoing.
- In this study we will look for biomarkers of pharmacological activity and early signs of clinical activity that may translate into reductions in colonic inflammation and promote mucosal healing in patients with moderate-to-severe UC,”.
